Drugs / CEPADACURSEN SODIUM
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03427710 | Feb 2018 → Feb 2020 | hyperlipidemia | Civi Biopharma, Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT04164888 | Nov 2019 → Jun 2020 | hyperlipidemia | Civi Biopharma, Inc. | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CEPADACURSEN SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650257 ↗ |
| Known as | CIVI 007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04164888 ↗ |
| Action | Inhibit | “a PCSK9 inhibitor” NCT04164888 ↗ |
| Route | Subcutaneous | “Subcutaneously Administered CiVi007” NCT03427710 ↗ |